Trial Results, Stock Splits, Share Repurchases, New Appointments, and Completed Acquisitions - Research Report on Incyte, Novo Nordisk, Thoratec, Alere, and Kindred Healthcare PR Newswire NEW YORK, December 18, 2013 NEW YORK, December 18, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Incyte Corporation (NASDAQ: INCY), Novo Nordisk A/S (NYSE: NVO), Thoratec Corp. (NASDAQ: THOR), Alere Inc. (NYSE: ALR), and Kindred Healthcare Inc. (NYSE: KND). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Incyte Corporation Research Report On December 9, 2013, Incyte Corporation (Incyte) presented the results of an interim analysis from a 12-week open-label, dose-escalation Phase II clinical trial involving more than 85 patients with intermediate or high-risk myelofibrosis (MF) for its proprietary oral JAK1 inhibitor, INCB39110, at the 2013 American Society of Hematology (ASH) Annual Meeting in New Orleans. Richard S. Levy, M.D., Incyte's Executive Vice President and Chief Drug Development and Medical Officer, stated, "With the interim analysis of this trial combined with data from two other proof-of-concept trials in rheumatoid arthritis and psoriasis, we have a better understanding of JAK1 as a disease target, and we're using this knowledge to focus the development of our broad portfolio of JAK1 inhibitors." Levy continued, "We are taking INCB39110, our most advanced JAK1 inhibitor, forward initially in solid tumors, starting with combinations that may not be as well-tolerated with a JAK1/JAK2 inhibitor as a result of the potential myelosuppressive effect of JAK2 inhibition." The Full Research Report on Incyte Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.AnalystsCorner.com/r/full_research_report/076e_INCY Novo Nordisk A/S Research Report On December 10, 2013, Novo Nordisk A/S (Novo Nordisk) announced that its Board of Directors has approved a stock split of the Novo Nordisk B shares listed on NASDAQ OMX Copenhagen and of the American Depositary Receipts (ADRs) listed on New York Stock Exchange (NYSE). Novo Nordisk reported that the trading unit of the Novo Nordisk B shares listed on the stock exchange in Copenhagen will be changed from DKK 1 to DKK 0.20, while the ratio of B shares to ADRs listed on NYSE will remain 1:1. Further, the Company stated that the changes in the trading units will be effective on January 2, 2014 for the Novo Nordisk B shares and on January 9, 2014 for the ADRs. The Full Research Report on Novo Nordisk A/S - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.AnalystsCorner.com/r/full_research_report/fee1_NVO Thoratec Corp. Research Report On December 9, 2013, Thoratec Corp. (Thoratec) announced that its Board of Directors has authorized a $200-million share repurchase program for its common stock, effective through the end of 2015. According to Thoratec, its previous share repurchase authorization is slated to expire at the end of 2013. Commenting on the repurchase authorization, Gary F. Burbach, Thoratec President and CEO, said, "This authorization reflects our strong financial position and commitment to a disciplined capital allocation strategy, along with continued confidence in our long-term growth opportunities. Funding our internal growth initiatives and pursuing attractive business development opportunities remain our top priorities, although this authorization provides the flexibility to also allocate capital to share repurchases in a measured and opportunistic fashion over time." The Full Research Report on Thoratec Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.AnalystsCorner.com/r/full_research_report/1bee_THOR Alere Inc. Research Report On December 12, 2013, Alere Inc. (Alere) announced the appointment of Regina M. Benjamin, MD, MBA to its Board of Directors, effective immediately. Commenting on the appointment, Ron Zwanziger, Alere Chairman and CEO, said, "Having served as America's Doctor, Regina brings invaluable experience and insights, as well as a longstanding commitment to improving health care outcomes - particularly for underserved populations. Her leadership in public health aligns perfectly with Alere's development of breakthrough technologies that enhance patient care." The Full Research Report on Alere Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.AnalystsCorner.com/r/full_research_report/5da1_ALR Kindred Healthcare Inc. Research Report On December 12, 2013, Kindred Healthcare Inc. (Kindred Healthcare) announced that its subsidiaries have successfully completed the acquisition of real estate associated with seven nursing centers that it currently leases from HCP, Inc. and its affiliates (HCP) for approximately $61 million. The Company had previously agreed to acquire the real estate associated with two other nursing centers from HCP and expects to close the acquisition of those two properties in Q1 2014. Further, it anticipates the transactions with HCP to be slightly accretive to its 2014 earnings. Paul J. Diaz, CEO of Kindred Healthcare, commented, "Purchasing the real estate of these nursing centers allows us to improve our capital structure as we enter the growth phase of our strategic plan." Diaz added, "We continue to explore opportunities to invest in our Integrated Care Markets, and our growing Care Management business and Kindred at Home." The Full Research Report on Kindred Healthcare Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.AnalystsCorner.com/r/full_research_report/ab58_KND EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. http://www.AnalystsCorner.com/ SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Trial Results, Stock Splits, Share Repurchases, New Appointments, and Completed Acquisitions - Research Report on Incyte, Novo
Press spacebar to pause and continue. Press esc to stop.